Stock DNA
Pharmaceuticals & Biotechnology
PKR 42,560 Million (Mid Cap)
17.00
NA
2.50%
-0.34
38.26%
5.69
Revenue and Profits:
Net Sales:
8,720 Million
(Quarterly Results - Jun 2025)
Net Profit:
790 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
10.68%
0%
10.68%
6 Months
29.83%
0%
29.83%
1 Year
137.72%
0%
137.72%
2 Years
355.63%
0%
355.63%
3 Years
301.93%
0%
301.93%
4 Years
258.81%
0%
258.81%
5 Years
310.06%
0%
310.06%
Hoechst Pakistan Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
16.63%
EBIT Growth (5y)
36.17%
EBIT to Interest (avg)
29.65
Debt to EBITDA (avg)
0.10
Net Debt to Equity (avg)
-0.29
Sales to Capital Employed (avg)
3.92
Tax Ratio
42.86%
Dividend Payout Ratio
70.11%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
44.09%
ROE (avg)
15.90%
Valuation key factors
Factor
Value
P/E Ratio
17
Industry P/E
Price to Book Value
5.64
EV to EBIT
7.67
EV to EBITDA
7.20
EV to Capital Employed
8.56
EV to Sales
1.25
PEG Ratio
0.43
Dividend Yield
2.65%
ROCE (Latest)
111.56%
ROE (Latest)
33.45%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Bullish
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
8,720.10
7,573.50
15.14%
Operating Profit (PBDIT) excl Other Income
1,565.60
1,334.00
17.36%
Interest
16.70
41.50
-59.76%
Exceptional Items
0.00
0.00
Consolidate Net Profit
789.80
553.20
42.77%
Operating Profit Margin (Excl OI)
179.50%
165.40%
1.41%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 15.14% vs 21.54% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 42.77% vs -15.18% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
26,747.80
21,368.90
25.17%
Operating Profit (PBDIT) excl Other Income
3,359.80
2,231.70
50.55%
Interest
144.50
174.80
-17.33%
Exceptional Items
18.90
62.10
-69.57%
Consolidate Net Profit
1,857.10
360.80
414.72%
Operating Profit Margin (Excl OI)
114.10%
89.80%
2.43%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 25.17% vs 15.13% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 414.72% vs 116.31% in Dec 2023
About Hoechst Pakistan Ltd. 
Hoechst Pakistan Ltd.
Pharmaceuticals & Biotechnology
Sanofi-Aventis Pakistan Limited (Sanofi) is a Pakistan-based company, which is engaged in the manufacturing and selling of pharmaceutical and consumer products. The Company's segment is manufacturing and selling of pharmaceutical and consumer products. The Company offers medicines, consumer healthcare products, generics and animal health products. Its products include oral anti-diabetics, such as Amaryl and Amaryl M, Daonil and Daonil - M, and Neodipar; insulins, such as Lantus, Apidra and SoloSTAR; cancer, such as Jevtana, Taxotere, Eloxatin and Fludara; pain management, such as No-Spa, Gardan, Muscoril and Profenid; allergy management, such as Telfast, Avil, Nasacort, Phenergan and Avomine; cough and cold, such as Rhinathiol and Tixylix; sleep disorders, such as Stilnox; emergency care, such as Haemaccel; cardiology, such as Plavix, CoPlavix, Aprovel, Co Aprovel, Clexane, Tritace, Co Tritacem and Winstor, and antibiotics, such as Tarivid, Claforan, Aventriax and Rulid.
Company Coordinates 
Company Details
Plot No. 23, Sector No. 22, Korangi Industrial Area, KARACHI None : 74900
Registrar Details






